An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Emma Guttman‐Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue
Topics & Concepts
Eczema Area and Severity IndexMedicineAtopic dermatitisPlaceboClinical endpointAdverse effectBody surface areaInternal medicineSeverity of illnessClinical trialDermatologyPathologyAlternative medicineDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisMast cells and histamine